Trial
NCT03525392
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Ipsen
Collaborators
—
Condition
Pancreatic Ductal Adenocarcinoma
Intervention
177Lu-3BP-227 (also called 177Lu-IPN01087)
Why stopped
Due to agreement to transfer rights for IPN01087 to an external partner, not due to safety concerns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-12-12